Differences in chemotaxis of human mesenchymal stem cells and cervical cancer cells
Tóm tắt
In the last decade, there has been a rapid expansion in tumor targeted therapy using mesenchymal stem cells (MSCs) based on their unique tropism towards cancer cells. Despite similarities in morphology, immunophenotype, and differential potent in vitro, MSCs originated from different tissues do not necessarily have equivalent biological behaviors. It is important to screen the most chemotactic MSCs to cancer cells. In this study, different MSCs were isolated from various human tissues including adipose, umbilical cord, amniotic membrane, and chorion. The chemotaxis of human MSCs to cervical cancer cells was measured by CCK-8, ELISA and Transwell invasion assays. Western blotting was performed to explore the underlying mechanisms. MSCs derived from distinct sources can be differently recruited to cervical cancer cells, among which chorion-derived MSC (CD-MSC) possessed the strongest tropic capacity. CXCL12 was found to be highly secreted by cervical cancer cells, in parallel with the expression of CXCR4 in all MSCs. CD-MSC displayed the highest level of CXCR4. These results indicated that CXCL12/CXCR4 pathway contributed to the different chemotaxis to cervical cancer cells of each MSCs. This study proposed that CD-MSC with the highest CXCR4 expression is a promising therapeutic vehicle for targeted therapy in cervical cancer.
Tài liệu tham khảo
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249
Zhao F, Qiao Y (2019) Cervical cancer prevention in China: a key to cancer control. Lancet 393:969–970
Bao H, Zhang L, Wang L et al (2018) Significant variations in the cervical cancer screening rate in China by individual-level and geographical measures of socioeconomic status: a multilevel model analysis of a nationally representative survey dataset. Cancer Med 7:2089–2100
Arbyn M, Weiderpass E, Bruni L et al (2020) Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 8:e191–e203
Wei M, Zhou W, Bi Y, Wang H, Liu Y, Zhang ZJ (2019) Rising mortality rate of cervical cancer in younger women in urban China. J Gen Intern Med 34:281–284
Koh WJ, Abu-Rustum NR, Bean S et al (2019) Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17:64–84
Griffiths MJ, Winship AL, Hutt KJ (2020) Do cancer therapies damage the uterus and compromise fertility? Hum Reprod Update 26:161–173
Spears N, Lopes F, Stefansdottir A et al (2019) Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update 25:673–693
Griffin MD, Ritter T, Mahon BP (2010) Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 21:1641–1655
Pittenger MF, Mackay AM, Beck SC et al (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143–147
Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726–736
Hu YL, Fu YH, Tabata Y, Gao JQ (2010) Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release 147:154–162
Chulpanova DS, Kitaeva KV, Tazetdinova LG, James V, Rizvanov AA, Solovyeva VV (2018) Application of mesenchymal stem cells for therapeutic agent delivery in anti-tumor treatment. Front Pharmacol 9:259
Kemp KC, Hows J, Donaldson C (2005) Bone marrow-derived mesenchymal stem cells. Leuk Lymphoma 46:1531–1544
Rodriguez AM, Elabd C, Amri EZ, Ailhaud G, Dani C (2005) The human adipose tissue is a source of multipotent stem cells. Biochimie 87:125–128
Ding DC, Chang YH, Shyu WC, Lin SZ (2015) Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant 24:339–347
Papait A, Vertua E, Magatti M, et al (2020) Mesenchymal stromal cells from fetal and maternal placenta possess key similarities and differences: potential implications for their applications in regenerative medicine. Cells 9.
Camernik K, Mihelic A, Mihalic R et al (2019) Skeletal-muscle-derived mesenchymal stem/stromal cells from patients with osteoarthritis show superior biological properties compared to bone-derived cells. Stem Cell Res 38:101465
Reinisch A, Etchart N, Thomas D et al (2015) Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood 125:249–260
Wu M, Zhang R, Zou Q et al (2018) Comparison of the biological characteristics of mesenchymal stem cells derived from the human placenta and umbilical cord. Sci Rep 8:5014
Horwitz EM, Le Blanc K, Dominici M et al (2005) Clarification of the nomenclature for MSC: the International society for cellular therapy position statement. Cytotherapy 7:393–395
Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. the International Society for Cellular Therapy position statement. Cytotherapy 8:315–317
Calloni R, Cordero EA, Henriques JA, Bonatto D (2013) Reviewing and updating the major molecular markers for stem cells. Stem Cells Dev 22:1455–1476
Mildmay-White A, Khan W (2017) Cell surface markers on adipose-derived stem cells: a systematic review. Curr Stem Cell Res Ther 12:484–492
Baer PC, Kuci S, Krause M et al (2013) Comprehensive phenotypic characterization of human adipose-derived stromal/stem cells and their subsets by a high throughput technology. Stem Cells Dev 22:330–339
Li W, Song Y, Pan C, Yu J, Zhang J, Zhu X. (2021) Aquaporin-8 is a novel marker for progression of human cervical cancer cells. Cancer Biomark.
Brown C, McKee C, Bakshi S et al (2019) Mesenchymal stem cells: cell therapy and regeneration potential. J Tissue Eng Regen Med 13:1738–1755
Li L, Guan Y, Liu H et al (2011) Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. ACS Nano 5:7462–7470
Deng W, Bivalacqua TJ, Chattergoon NN, Jeter JR Jr, Kadowitz PJ (2004) Engineering ex vivo-expanded marrow stromal cells to secrete calcitonin gene-related peptide using adenoviral vector. Stem Cells 22:1279–1291
Kern S, Eichler H, Stoeve J, Kluter H, Bieback K (2006) Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24:1294–1301
Mueller SM, Glowacki J (2001) Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem 82:583–590
Stenderup K, Justesen J, Clausen C, Kassem M (2003) Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 33:919–926
Wagner W, Ho AD, Zenke M (2010) Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B 16:445–453
Yang YK, Ogando CR, Wang See C, Chang TY, Barabino GA (2018) Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro. Stem Cell Res Ther 9:131
Siennicka K, Zolocinska A, Debski T, Pojda Z (2021) Comparison of the donor age-dependent and in vitro culture-dependent mesenchymal stem cell aging in rat model. Stem Cells Int 2021:6665358
Fafian-Labora JA, Morente-Lopez M, Arufe MC (2019) Effect of aging on behaviour of mesenchymal stem cells. World J Stem Cells 11:337–346
Ridge SM, Sullivan FJ, Glynn SA (2017) Mesenchymal stem cells: key players in cancer progression. Mol Cancer 16:31
Li P, Gong Z, Shultz LD, Ren G (2019) Mesenchymal stem cells: From regeneration to cancer. Pharmacol Ther 200:42–54
Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C (2010) Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 9:129
Garcia-Rocha R, Moreno-Lafont M, Mora-Garcia ML et al (2015) Mesenchymal stromal cells derived from cervical cancer tumors induce TGF-beta1 expression and IL-10 expression and secretion in the cervical cancer cells, resulting in protection from cytotoxic T cell activity. Cytokine 76:382–390
de Lourdes M-G, Garcia-Rocha R, Morales-Ramirez O et al (2016) Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions. J Transl Med 14:302
Montesinos JJ, Mora-Garcia Mde L, Mayani H et al (2013) In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity. Stem Cells Dev 22:2508–2519
Yi T, Song SU (2012) Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res 35:213–221
Galipeau J (2013) The mesenchymal stromal cells dilemma–does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 15:2–8
Fakiruddin KS, Ghazalli N, Lim MN, Zakaria Z, Abdullah S (2018) Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour. Int J Mol Sci 19.
Yadav SS, Prasad SB, Prasad CB et al (2016) CXCL12 is a key regulator in tumor microenvironment of cervical cancer: an in vitro study. Clin Exp Metastasis 33:431–439
Huang Y, Zhang J, Cui ZM, Zhao J, Zheng Y (2013) Expression of the CXCL12/CXCR4 and CXCL16/CXCR6 axes in cervical intraepithelial neoplasia and cervical cancer. Chin J Cancer 32:289–296
Zheng J, Li H, He L et al (2019) Preconditioning of umbilical cord-derived mesenchymal stem cells by rapamycin increases cell migration and ameliorates liver ischaemia/reperfusion injury in mice via the CXCR4/CXCL12 axis. Cell Prolif 52:e12546